Group 1 - Bidu Pharmaceutical (688073.SH) announced the termination of its plan to acquire a stake in Zhuhai Weibo Investment Co., Ltd. and raise matching funds, which also halts its significant asset restructuring plan involving Combi-Blocks, Inc. [1][3] - The termination was primarily due to Weibo Investment's failure to complete the acquisition of 100% of Combi-Blocks, Inc. within the agreed timeframe, leading to an automatic termination of the agreement. [1][3] - Combi-Blocks, Inc. is a drug molecular building block company based in San Diego, USA, with a strong market presence in Europe and the US, particularly in boronic acid products. [3] Group 2 - The termination of the transaction impacts Bidu Pharmaceutical's strategic deployment aimed at enhancing its competitiveness in the drug molecular building block sector and accelerating its international expansion. [3] - Following the termination, the company committed to not planning any major asset restructuring for one month from the disclosure date. [3] - According to the company's performance report, Bidu Pharmaceutical achieved a revenue of 1.102 billion yuan in 2024, a year-on-year increase of 0.93%, and a net profit of 123 million yuan, up 12.07% year-on-year, while the net profit excluding non-recurring items decreased by 11.20% to 109 million yuan. [3]